Key clinical point: Dupilumab (Dupixent) significantly reduced patient-reported dysphagia among adults with eosinophilic esophagitis.
Major finding: Change in the Straumann Dysphagia Instrument (SDI) score from baseline to week 10, the study primary endpoint, was significantly improved for dupilumab (least squares mean change of –3.0 from baseline, versus –1.3 for placebo; P = .0304).
Study details: A phase 2 trial including 47 adults with EoE randomized to dupilumab or placebo.
Disclosures: The research was sponsored by Sanofi and Regeneron Pharmaceuticals. Several study coauthors indicated that they were current or former employees of those companies. Other study authors provided disclosures related to Regeneron, Adare, Allakos, Receptos/Celgene, Meritage, Shire, Alivio, Banner, Calypso, Enumeral, EsoCap, Glax-oSmithKline, and Robarts, among others.
Hirano I et al. Gastroenterology. 2019 Oct 5. doi: 10.1053/j.gastro.2019.09.042.